留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

清蛋白作为药物载体的PEG化修饰研究进展

周琴琴,  陈建明

downloadPDF
文章导航 > 药学实践与服务  > 2014 >  32(4): 241-245,265
周琴琴, 陈建明. 清蛋白作为药物载体的PEG化修饰研究进展[J]. 药学实践与服务, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001
引用本文: 周琴琴, 陈建明. 清蛋白作为药物载体的PEG化修饰研究进展[J]. 药学实践与服务, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001
shu
ZHOU Qinqin, CHEN Jianming. Research advances of PEGylation modification of albumin as drug carrier[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001
Citation: ZHOU Qinqin, CHEN Jianming. Research advances of PEGylation modification of albumin as drug carrier[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001
shu

清蛋白作为药物载体的PEG化修饰研究进展

doi: 10.3969/j.issn.1006-0111.2014.04.001
  • 1.

    福建中医药大学药学院药物制剂教研室, 福建 福州 350108;第二军医大学药学院药剂学教研室 上海 200433

  • 2.

    第二军医大学药学院药剂学教研室 上海 200433

Research advances of PEGylation modification of albumin as drug carrier

  • 1.

    Department of Pharmaceutical Preparations, School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China;Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 2.

    Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 摘要: 清蛋白(白蛋白)是一种理想的药物载体,但由于其在体内半衰期短以及易被酶降解等缺点限制了其应用,然而根据其具有多个修饰位点的结构特点,可通过PEG修饰延长循环时间,阻碍酶的作用等。目前,PEG修饰清蛋白仍处于研究阶段,已有较多关于PEG修饰清蛋白的研究,例如PEG修饰所起的作用、对清蛋白及其制剂的影响,以及修饰位点的选择等。本文对清蛋白的PEG化修饰的相关研究进行综述。
    Abstract: Albumin is an ideal drug carrier, but its application was limited because of the shortcomings of short half-life and susceptible to enzymatic degradation in vivo.However, according to its structural features, albumin has a plurality of modification sites, which can be modified by PEG modifier to extend the cycle time and obstruct the action of the enzyme.Currently, the PEG-modified albumin is still in the research stage, and there have been many studies about PEG-modified albumin, such as the role of PEG modification, the effects on albumin and its preparations and the modification sites selection.The article reviewed the related studies about the PEGylation of albumin.
  • [1] Gong J, Huo M, Zhou J, et al. Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles[J].Int J Pharm, 2009,376(1-2): 161-168.
    [2] Hasan K, Seyed AS, Amir M, et al. Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology[J].AAPS Pharm Sci Tech, 2010, 11(3): 1206-1211.
    [3] Zhang SF, Cezary K, Michael RD, et al. Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery[J].Biomaterials, 2010, 31(5): 952-963.
    [4] Marion GA, Mahler HC, Klaus L. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients[J].Int J Pharm, 2008, 363(1-2): 162-169.
    [5] Bitten P, Conan JF, Peter W, et al. Effects of PEG size on structure, function and stability of PEGylated BSA[J].Eur J Pharm Biopharm, 2011, 79(2): 399-405.
    [6] Zhao T, Cheng YN, Tan HN, et al. Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice[J].Biolog Pharm Bull, 2012, 35(3): 280-288.
    [7] Zhao T, Yang Y, Zong AZ, et al. N-terminal PEGylation of human serum albumin and investigation of its pharmacokinetics and pulmonary microvascular retention[J].Biol Sci Trends, 2012, 6(2): 81-88.
    [8] Wu L, Martin CG, Stanley SD, et al. Preparation and characterisation of rose bengal-loaded surface-modified albumin nanoparticles[J].J Contr Rel, 2011, 71(1): 117-126.
    [9] Franco D, Silvia A, Paola B, et al. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics[J].J Contr Rel, 2001, 76(1-2): 107-117.
    [10] Pedro C, Amy GT, Ananda K. Volume resuscitation from hemorrhagic shock with albumin and hexaPEGylated human serum albumin[J].Resuscitation, 2008, 79(1): 139-146.
    [11] Moghimi SM. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers[J].Biochim Biophys Acta, 2002, 1590(1-3): 131-139.
    [12] 周 莉, 罗贵民, 高蛛娟, 等. 聚乙二醇修饰牛血请白蛋白[J].吉林大学自然科学学报,1997, (4): 63-66.
    [13] Jesse VJ, Tatsiana L, Richard NZ, et al. Nanoparticle PEGylation for imaging and therapy[J].Nanomedicine, 2001, 6(4): 715-728.
    [14] Wu L, Martin CG, Etienne S, et al. Preparation and in vitro characterization of HSA-mPEG nanoparticles[J].Int J Pharm, 1999, 189(2): 161-170.
    [15] 孙诚谊, 刘建刚, 钱志勇, 等. 聚乙二醇修饰与未修饰磁性5-氟尿嘧啶白蛋白微球体外性质的比较[J].消化肿瘤杂志, 2008, 1(2): 110-113.
    [16] Beatriz F, Bibiana N, Hernan DN, et al. Thermal features of the bovine serum albumin unfolding by polyethylene glycols[J].Int J Biol Macromol, 1999, 26(1): 23-33.
    [17] Gianfranco P, Francesco MV. State of the art in PEGylation: the great versatility achieved after forty years of research[J].J Contr Rel, 2012, 161(2): 461-472.
    [18] 徐 超. 聚乙二醇修饰人血清白蛋白及其纳米微球制备[D]. 合肥工业大学, 2007.
    [19] Liu W, Zhang ZQ, Liu CM, et al. Effect of molecular patch modification on the stability of dynamic high-pressure microfluidization treated trypsin[J].Innov Food Sci Emerg Tech, 2012, 16: 349-354.
    [20] Hou BB, Li SR, Li XH, et al. Design, preparation and in vitro bioactivity of mono-PEGylated recombinant hirudin[J].Chin J Chem Eng, 2007, 15(6): 775-780.
    [21] Veronese FM. Introduction and overview of peptide and protein PEGylation: a review of problems and solution[J].Biomaterials,2001, 22(5): 405-417.
    [22] Hu JL, Walter S. N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH[J].Int J Pharm, 2011, 413(1-2): 140-146.
    [23] Stewart AJ, Blindauer CA, Berezenko S, et al. Role of Tyr84 in controlling the reactivity of Cys34 of human albumin[J].FEBS J, 2005, 272(2): 353-362.
    [24] Octaaf JMB, Jan FAL, Marcel JEF, et al. The molecular mechanism of the neutral-to-base transition of human serum albumin[J].J Biol Chem, 1989, 264(2): 953-959.
    [25] Kim SH, Jeong JH, Joe CO, et al. Folate receptor mediated intracellular protein delivery using PLL-PEG-FOL conjugate[J].J Contr Rel, 2005,103: 625-634.
    [26] 袁 飞, 王树斌, 彭志平, 等. 表皮生长因子受体靶向纳米载体荷载c-erbB2反义寡脱氧核苷酸对人乳腺癌SK-BR3细胞的摄取和滞留[J].中国组织工程研究与临床康复, 2009,13(16): 3084-3088.
    [27] Choi N, Kim SM, Hong KS, et al. The use of the fusion protein RGD-HSA-TIMP2 as a tumor targeting imaging[J].Biomaterials, 2011, 32: 7151-7158.
    [28] Parikh T, Bommana MM, Squillante E. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain[J].Eur J Pharm Biopharm, 2010, 74: 442-450.
    [29] Zensi A, Begley D, Pontikis C, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurons[J].J Contr Rel, 2009, 137: 78-86.
    [30] Kreuter J, Hekmatara T, Dreis S, et al. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain[J].J Contr Rel, 2007, 118: 54-58.
    [31] Ulbrich K, Hekmatara T, Herbert E, et al. Transferrin and transferrin-receptor-antibody modified nanoparticles enable drug delivery across the blood-brain barrier(BBB)[J]. Eur J Pharm Biopharm, 2009, 71: 251-256.
  • [1] 杨嘉宁, 赵一颖, 肖伟.  七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
    [2] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
    [3] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [4] 崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华.  肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404006
    [5] 何静, 安晔, 张朝绅.  复方黑参滴丸与复方黑参丸药效学实验比较研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404009
    [6] 陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾.  基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 1-8. doi: 10.12206/j.issn.2097-2024.202401073
    [7] 邹思, 吴岩斌, 吴锦忠, 吴建国, 黄家兴.  虎奶菇菌核多糖功能化纳米硒抗疲劳功效研究 . 药学实践与服务, 2024, 42(10): 426-432. doi: 10.12206/j.issn.2097-2024.202206072
    [8] 刘汝雄, 杨万镇, 涂杰, 盛春泉.  铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2997
  • HTML全文浏览量:  245
  • PDF下载量:  371
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-08-11
  • 修回日期:  2013-12-25

清蛋白作为药物载体的PEG化修饰研究进展

doi: 10.3969/j.issn.1006-0111.2014.04.001
  • 1. 福建中医药大学药学院药物制剂教研室, 福建 福州 350108;第二军医大学药学院药剂学教研室 上海 200433
  • 2. 第二军医大学药学院药剂学教研室 上海 200433
  • 收稿日期: 2013-08-11
  • 修回日期: 2013-12-25

摘要: 清蛋白(白蛋白)是一种理想的药物载体,但由于其在体内半衰期短以及易被酶降解等缺点限制了其应用,然而根据其具有多个修饰位点的结构特点,可通过PEG修饰延长循环时间,阻碍酶的作用等。目前,PEG修饰清蛋白仍处于研究阶段,已有较多关于PEG修饰清蛋白的研究,例如PEG修饰所起的作用、对清蛋白及其制剂的影响,以及修饰位点的选择等。本文对清蛋白的PEG化修饰的相关研究进行综述。

English Abstract

周琴琴, 陈建明. 清蛋白作为药物载体的PEG化修饰研究进展[J]. 药学实践与服务, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001
引用本文: 周琴琴, 陈建明. 清蛋白作为药物载体的PEG化修饰研究进展[J]. 药学实践与服务, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001
shu
ZHOU Qinqin, CHEN Jianming. Research advances of PEGylation modification of albumin as drug carrier[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001
Citation: ZHOU Qinqin, CHEN Jianming. Research advances of PEGylation modification of albumin as drug carrier[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001
shu

    全文HTML

参考文献 (31)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计